AtriCure (ATRC)
(Delayed Data from NSDQ)
$26.87 USD
+0.62 (2.36%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $26.88 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$26.87 USD
+0.62 (2.36%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $26.88 +0.01 (0.04%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Zacks News
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
by Zacks Equity Research
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
by Zacks Equity Research
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
AtriCure (ATRC) Reports Q2 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure (ATRC) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -13.33% and 0.04%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Gains China Approval for AtriClip LAA System
by Zacks Equity Research
AtriCure (ATRC) receives NMPA approval to market AtriClip Left Atrial Appendage Exclusion System in China, marking a significant step in global expansion.
Abbott (ABT) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 3.64% and 0.22%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Compared to Estimates, AtriCure (ATRC) Q1 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -19.05% and 2.19%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
AtriCure's (ATRC) cryoSPHERE+ Probe to Aid in Pain Management
by Zacks Equity Research
AtriCure (ATRC) unveils its cryoSPHERE+ cryoablation probe, which is intended to reduce freeze times and aid in postoperative pain management.
Here's What Key Metrics Tell Us About AtriCure (ATRC) Q4 Earnings
by Zacks Equity Research
The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 4.55% and 0.04%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Seeking Clues to AtriCure (ATRC) Q4 Earnings? A Peek Into Wall Street Projections for Key Metrics
by Zacks Equity Research
Get a deeper insight into the potential performance of AtriCure (ATRC) for the quarter ended December 2023 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Wall Street Analysts Predict a 36.34% Upside in AtriCure (ATRC): Here's What You Should Know
by Zacks Equity Research
The consensus price target hints at a 36.3% upside potential for AtriCure (ATRC). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
All You Need to Know About AtriCure (ATRC) Rating Upgrade to Buy
by Zacks Equity Research
AtriCure (ATRC) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
AtriCure (ATRC) Reports Q3 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
Although the revenue and EPS for AtriCure (ATRC) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
AtriCure (ATRC) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for AtriCure (ATRC) give a sense of how the business performed in the quarter ended June 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
AtriCure (ATRC) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 55.56% and 3.05%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 32.35% and 6.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Moves 7.5% Higher: Will This Strength Last?
by Zacks Equity Research
AtriCure (ATRC) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
AtriCure (ATRC) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of 50% and 0.02%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Canopy Growth Corporation (CGC) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Canopy Growth Corporation (CGC) delivered earnings and revenue surprises of -169.23% and 11.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
AtriCure (ATRC) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
AtriCure (ATRC) delivered earnings and revenue surprises of -8% and 2.26%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Baxter International (BAX) Q3 Earnings Match Estimates
by Zacks Equity Research
Baxter (BAX) delivered earnings and revenue surprises of 0% and 0.03%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Will Nephros Inc. (NEPH) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Nephros Inc. (NEPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analysts Estimate AtriCure (ATRC) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
AtriCure (ATRC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.